Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.73 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.73 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.73 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.44 |
| ▸ | SHMT1 | P34896 | 2/20 | 0.44 |
| ▸ | SHMT2 | P34897 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2431805 | 0.84 | ALDH1A1 (1.00) | ALDH1A1L3MBTL1TDP1NPC1HTR2C | |
| SCHEMBL16619009 | 0.83 | ALDH1A1 (0.73) | ALDH1A1L3MBTL1TDP1NPC1HTR2C | |
| SCHEMBL18015824 | 0.83 | ALDH1A1 (0.73) | ALDH1A1L3MBTL1TDP1NPC1HTR2C | |
| SCHEMBL793263 | 0.83 | ALDH1A1 (0.50) | ALDH1A1L3MBTL1TDP1NUDT1SHMT1 | |
| SCHEMBL21883091 | 0.81 | HTR2B (0.54) | ALDH1A1L3MBTL1TDP1CYP19A1NUDT1 | |
| SCHEMBL15356487 | 0.81 | MPL (0.50) | ALDH1A1L3MBTL1TDP1NPC1LMNA | |
| SCHEMBL16619626 | 0.80 | L3MBTL1 (0.69) | ALDH1A1L3MBTL1TDP1NPC1HTR2C | |
| SCHEMBL5930632 | 0.80 | ALDH1A1 (0.69) | ALDH1A1L3MBTL1TDP1NPC1HTR2C | |
| SCHEMBL18015816 | 0.80 | L3MBTL1 (0.69) | ALDH1A1L3MBTL1TDP1NPC1HTR2C | |
| SCHEMBL4727339 | 0.79 | ALDH1A1 (0.46) | ALDH1A1L3MBTL1TDP1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242535-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL MYERS SQUIBB CO (US) | 2023-08-03 | — | — | US | disclosed |
| US-10822343-B2 | Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregation | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-11-03 | — | — | US | disclosed |
| US-20200123160-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL MYERS SQUIBB CO (US) | 2020-04-23 | — | — | US | disclosed |
| EP-3632919-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | Bristol-Myers Squibb Company (US) | 2020-04-08 | — | — | EP | disclosed |
| EP-3243826-B1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL MYERS SQUIBB CO (US) | 2019-10-30 | — | — | EP | disclosed |
| US-10428077-B2 | Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregation | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-10-01 | — | — | US | disclosed |
| EP-3243826-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | Bristol-Myers Squibb Company (US) | 2017-11-15 | — | — | EP | disclosed |
| US-20170247395-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL-MYERS SQUIBB COMPANY | 2017-08-31 | — | — | US | disclosed |
| US-20170247395-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL-MYERS SQUIBB COMPANY | 2017-08-31 | — | — | US | disclosed |
| EP-2841437-B1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL MYERS SQUIBB CO (US) | 2017-07-05 | — | — | EP | disclosed |
| US-20150094297-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL-MYERS SQUIBB COMPANY | 2015-04-02 | — | — | US | disclosed |
| US-8927688-B2 | PAR4 agonist peptides | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-01-06 | — | — | US | disclosed |
| US-8927688-B2 | PAR4 agonist peptides | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-01-06 | — | — | US | disclosed |
| US-20130289238-A1 | PAR4 AGONIST PEPTIDES | BRISTOL-MYERS SQUIBB COMPANY | 2013-10-31 | — | — | US | disclosed |
| US-20130289238-A1 | PAR4 AGONIST PEPTIDES | BRISTOL-MYERS SQUIBB COMPANY | 2013-10-31 | — | — | US | disclosed |
| US-7041690-B2 | Inhibitors of HCV NS5B polymerase | PHARMACIA & UPJOHN COMPANY, LLC (US) | 2006-05-09 | — | — | US | disclosed |
| US-20060004063-A1 | Inhibitors of HCV NS5B polymerase | PHARMACIA & UPJOHN COMPANY, LLC | 2006-01-05 | — | — | US | disclosed |
| EP-1532128-A1 | INHIBITORS OF HCV NS5B POLYMERASE | Pharmacia & Upjohn Company LLC (US) | 2005-05-25 | — | — | EP | disclosed |
| US-20040142980-A1 | Inhibitors of HCV NS5B polymerase | PHARMACIA & UPJOHN COMPANY | 2004-07-22 | — | — | US | disclosed |
| WO-2004002977-A1 | INHIBITORS OF HCV NS5B POLYMERASE | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428077-B2 | Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregation | F2RL3, TMPRSS4, F2R | ALDH1A1 2559/4885L3MBTL1 3317/4885TDP1 993/4885 |
| US-20200123160-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | F2RL3, TMPRSS4, F2R | ALDH1A1 2559/4885L3MBTL1 3317/4885TDP1 993/4885 |
| US-20040142980-A1 | Inhibitors of HCV NS5B polymerase | POLRMT, POLR1E, CTDSP1 | ALDH1A1 832/4885L3MBTL1 3761/4885TDP1 1545/4885 |
| US-20130289238-A1 | PAR4 AGONIST PEPTIDES | F2RL3, F2R, F2RL1 | ALDH1A1 4720/4885L3MBTL1 1492/4885TDP1 2382/4885 |
| US-20150094297-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | F2RL3, F2R, TMPRSS4 | ALDH1A1 2611/4885L3MBTL1 3305/4885TDP1 965/4885 |
| US-20230242535-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | F2RL3, F2R, TMPRSS4 | ALDH1A1 2611/4885L3MBTL1 3305/4885TDP1 965/4885 |
| US-20170247395-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | F2RL3, TMPRSS4, F2R | ALDH1A1 2559/4885L3MBTL1 3317/4885TDP1 993/4885 |
| US-20060004063-A1 | Inhibitors of HCV NS5B polymerase | POLRMT, EIF5B, POLI | ALDH1A1 1400/4885L3MBTL1 4022/4885TDP1 2026/4885 |
| US-10822343-B2 | Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregation | F2RL3, TMPRSS4, F2R | ALDH1A1 2559/4885L3MBTL1 3317/4885TDP1 993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.